Compare APPF & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPF | ARWR |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 8.0B |
| IPO Year | 2015 | 2009 |
| Metric | APPF | ARWR |
|---|---|---|
| Price | $156.56 | $60.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $288.70 | $81.50 |
| AVG Volume (30 Days) | 321.0K | ★ 2.0M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ 3.88 | 0.22 |
| Revenue | ★ $950,822,000.00 | $16,142,321.00 |
| Revenue This Year | $19.69 | N/A |
| Revenue Next Year | $16.52 | N/A |
| P/E Ratio | ★ $40.52 | $277.32 |
| Revenue Growth | ★ 19.72 | N/A |
| 52 Week Low | $150.12 | $10.92 |
| 52 Week High | $325.90 | $76.76 |
| Indicator | APPF | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 33.71 | 52.23 |
| Support Level | N/A | $60.60 |
| Resistance Level | $191.16 | $66.37 |
| Average True Range (ATR) | 6.55 | 3.03 |
| MACD | -0.45 | 0.76 |
| Stochastic Oscillator | 25.66 | 61.58 |
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.